Cargando…
Dual Actions of Ketorolac in Metastatic Ovarian Cancer
Cytoreductive surgery and chemotherapy are cornerstones of ovarian cancer treatment, yet disease recurrence remains a significant clinical issue. Surgery can release cancer cells into the circulation, suppress anti-tumor immunity, and induce inflammatory responses that support the growth of residual...
Autores principales: | Hudson, Laurie G., Cook, Linda S., Grimes, Martha M., Muller, Carolyn Y., Adams, Sarah F., Wandinger-Ness, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721416/ https://www.ncbi.nlm.nih.gov/pubmed/31344967 http://dx.doi.org/10.3390/cancers11081049 |
Ejemplares similares
-
The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
por: Grimes, Martha M., et al.
Publicado: (2021) -
Agent-based modeling predicts RAC1 is critical for ovarian cancer metastasis
por: Rivera, Melanie, et al.
Publicado: (2022) -
Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase
por: Hudson, Laurie G., et al.
Publicado: (2018) -
Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
por: Steinkamp, Mara P., et al.
Publicado: (2023) -
Ketorolac trometamina y nalbufina : estudio comparativo/
por: Morgan Pérez, Martha Elena
Publicado: (1994)